PSMA-RLT in patients with metastatic hormone-sensitive prostate cancer: a retrospective study

A Banda, BM Privé, Y Allach, MJM Uijen, SMB Peters… - Cancers, 2022 - mdpi.com
Simple Summary Prostate-specific membrane antigen-direct radioligand therapy is a novel
treatment for patients with castration-resistant prostate cancer. Yet, given the mode of action …

[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study

S Satapathy, MP Yadav, S Ballal, RK Sahoo… - European Journal of …, 2024 - Springer
Abstract Purpose The use of [177Lu] Lu-PSMA-617 radioligand therapy has become
increasingly recognized as a viable therapeutic approach for patients in the advanced …

Promising Therapeutic Activity of 177Lu-PSMA-617 in Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Pilot Experience

S Satapathy, MP Yadav, S Ballal… - Clinical Nuclear …, 2024 - journals.lww.com
Purpose 177 Lu-PSMA-617 has been shown to improve survival outcomes in patients with
end-stage metastatic castration-resistant prostate cancer. However, data in earlier lines …

Estimation of absorbed dose to salivary glands in mCRPC patients undergoing 177 Lu-PSMA-617 radioligand therapy using quantitative SPECT-CT at single time …

K Kaur, S Nagi, S Satapathy, P Aggarwal… - Nuclear Medicine …, 2024 - journals.lww.com
Objective 177 Lu-PSMA-617-radioligand therapy (RLT) has shown promising therapeutic
role in patients with metastatic castration-resistant prostate cancer. However, off-target …

Efficacy and Safety of 177Lu-PSMA-617 in Combination with Radical Prostatectomy and Bilateral Orchiectomy in Men with Castrate-Sensitive Metastatic Prostate …

SA Soudmand, S Hoseinzadeh, M Moosavi… - Urology … - journals.sbmu.ac.ir
Objective: To investigate the efficacy and safety of 177Lu-PSMA-617 in combination with
radical prostatectomy and bilateral orchiectomy in adult male patients with castrate-sensitive …